ACT HEALTHY: A Combined Cognitive-Behavioral Depression and Medication Adherence Treatment for HIV-Infected Substance Users

Cognitive and Behavioral Practice

Volumn 17, Issue 3, 2010, Pages 309-321

  Daughters, Stacey B ^a   Magidson, Jessica F ^a   Schuster, Randi M ^a   Safren, Steven A ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; COMBOVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; QUETIAPINE; RITONAVIR; SERTRALINE; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; ALCOHOLIC BEVERAGE; ARTICLE; CANNABIS SMOKING; CASE REPORT; COCAINE DEPENDENCE; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; HEROIN DEPENDENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESIDENTIAL CARE; SUBSTANCE ABUSE;

EID: 77953617744     PISSN: 10777229     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpra.2009.12.003     Document Type: Article

References (60)

1. Aharonovich E., Hasin D.S., Brooks A.C., Liu X., Bisaga A., Nunes E.V. Cognitive deficits predict low treatment retention in cocaine dependent patients. Drug and Alcohol Dependence 2006, 81:313-322.
2. Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, DC, Author. (4th ed.).
3. Armento M.E., Hopko D.R. Behavioral activation of a breast cancer patient with coexistent major depression and generalized anxiety disorder. Clinical Case Studies 2009, 8:25-37.
4. Armento M.E., Hopko D.R. The Environmental Reward Observation Scale (EROS): Development, validity, and reliability. Behavioral Therapy 2007, 38:107-119.
5. Avins A., Woods W., Lindan C., Hudes E., Clark W., Hulley S. HIV infection and risk behaviors among heterosexuals in alcohol treatment programs. Journal of the American Medical Association 1994, 271:515-518.
6. Bangsberg D.R., Hecht F.M., Charlebois E.D., Zolopa A.R., Holodniy M., Sheiner L., Bamberger J.D., et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2005, 357-366.
7. Beck A.T., Steer R., Ball G. Beck Depression Inventory-II 1996, San Antonio, The Psychological Corporation.
8. Berwick D.M. Controlling variation in health care: A consultation from Walter Shewhart. Medical Care 1991, 29:1212-1225.
9. Bing E.G., Burnam M.A., Longshore D., Fleishman J.A., Sherbourne C.D., London A.S., et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Archives of General Psychiatry 2001, 58:721-728.
10. Brooner R., King V., Kidorf M., Schmidt C., Bigelow G. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Archives of General Psychiatry 1997, 54:71-80.
11. Chesney M., Morin M., Sherr L. Adherence to HIV combination therapy. Social Science Medicine 2000, 50:1599-1605.
12. Conrad P.J., Stewart S.H. A critical look at dual-focused cognitive-behavioral treatments for comorbid substance use and psychiatric disorders: Strengths, limitations, and future directions. Journal of Cognitive Psychotherapy 2005, 19:261-284.
13. Cook R.L., Sereika S.M., Hunt S.C., Woodward W.C., Erlen J.A., Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. Journal of General Internal Medicine 2001, 16:83-88.
14. Cuijpers P., van Straten F., Smit A. Psychological treatments of subthreshold depression: A meta-analytic review. Acta Psychiatrica Scandinavica 2007, 115:434-441.
15. Daughters S.B., Braun A.R., Sargeant M.N., Reynolds E.R., Hopko D., Blanco C., Lejuez C.W. Effectiveness of a brief behavioral treatment for inner-city illicit drug users with elevated depressive symptoms: The Life Enhancement Treatment for Substance Use (LETS ACT!). The Journal of Clinical Psychiatry 2008, 69:122-129.
16. Dimidjian S., Hollon S.D., Dobson K.S., Schmaling K.B., Kohlenberg R.J., Addis M.E., Gallop R., McGlinchey J.B., Markley D.K., Gollan J.K., Atkins D.C., Dunner D.L., Jacobson N.S. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. Journal of Consulting and Clinical Psychology 2006, 74:658-670.
17. Ekers D., Richards D., Gilbody S. A meta-analysis of randomized trials of behavioural treatment of depression. Psychological Medicine 2008, 38(5):611-623.
18. Evans D.L., Ten Have S.D., Gettes D.R., Morrison M., Chiappini M.S., Brinker-Spence P. Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. American Journal of Psychiatry 2002, 159:1752-1759.
19. First M.B., Gibbon M., Spitzer R.L., Williams J.B., Benjamin L.S. Structured Clinical Interview for DSM-IV Axis II Personality Disorders 1997, Biometrics Research, New York State Psychiatric Institute, New York.
20. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. (SCID-I/NP) 2002, Biometrics Research, New York State Psychiatric Institute, New York.
21. Ford J.D., Gelernter J., DeVoe J.S., Weiss R.D., Brady K., Farrer L., Kranzler H.R. Association of psychiatric and substance use disorder comorbidity with cocaine dependence severity and treatment utilization in cocaine-dependent individuals. Drug and Alcohol Dependence 2009, 99:193-203.
22. Gottschalk C., Beauvais J., Hart R., Kosten T. Cognitive function and cerebral perfusion during cocaine abstinence. American Journal of Psychiatry 2001, 158:540-545.
23. Greene K., Frey L., Derlega V. Interpersonalizing AIDS: Attending to the personal and social relationships of individuals living with HIV and/or AIDS. Journal of Social & Personal Relationships 2002, 19:5-18.
24. Hasin D., Goodwin R., Stinson F., Grant B. Epidemiology of major depressive disorder: Results From The National Epidemiologic Survey on Alcoholism and Related Conditions. Archives of General Psychiatry 2005, 62:1097-1106.
25. Herbert T., Cohen S. Depression and immunity: A meta-analytic review. Psychological Bulletin 1993, 113:472-486.
26. Hopko D.R., Bell J.L., Armento M.E., Hunt M.K., Lejuez C.W. Behavior therapy for depressed cancer patients in primary care. Psychotherapy: Theory, Research, Practice, Training 2005, 42:236-243.
27. Hopko D.R., Bell J.L., Armento M., Mullane C., Lejuez C.W., Wolf N., Robertson S. Cognitive-behavior therapy for depressed cancer patients in a medical care setting. Behavior Therapy 2008, 39:126-136.
28. Hsiung P.C., Fang C.T., Chang Y.Y., Chen M.Y., Wang J.D Comparison of WHOQOL-BREF and SF-36 in patients with HIV infection. Quality of Life Research 2005, 14:141-150.
29. Ironson G., O'Cleirigh C., Fletcher M., Laurenceau J., Balbin E., Klimas N., Schneiderman N., Solomon G. Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. Psychosomatic Medicine 2005, 67:1013-1021.
30. Jacobson N., Dobson K., Truax P., Addis M., Koerner K., Gollan J., et al. A component analysis of cognitive-behavioral treatment for depression. Journal of Consulting and Clinical Psychology 1996, 64:295-304.
31. Kanter J.W., Mulick P.S., Busch A.M., Berlin K.S., Martell C.R. The Behavioral Activation for Depression Scale (BADS): Psychometric properties and factor structure. Journal of Psychopathology and Behavioral Assessment 2007, 29:191-202.
32. Kokkevi A., Stefanis C. Drug abuse and psychiatric co-morbidity. Comprehensive Psychiatry 1995, 36:329-337.
33. Kwiatkowski C.E., Booth R.E. HIV-seropositive drug users and unprotected sex. AIDS and Behavior 1998, 2:151-159.
34. Lejuez C.W., Hopko D.R., Hopko S.D. The brief behavioral activation treatment for depression: A comprehensive patient guide 2001, Pearson Custom, Boston.
35. Lejuez C.W., Hopko D.R., LePage Hopko S.B., McNeil D.W. A brief behavioral activation treatment for depression. Cognitive and Behavioral Practice 2001, 8:164-175.
36. Maier W., Philipp M. Improving the assessment of severity of depressive states: A reduction of the Hamilton Depression Rating Scale. Pharmacopsychiatry 1985, 18:114-115.
37. McCoy H.V., Messiah S.E., Zhao W Improving access to primary health care for chronic drug users: An innovative systemic intervention for providers. Journal of Behavioral Health Services & Research 2002, 29:445-457.
38. McHorney C., Ware J., Lu J., Sherbourne C. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994, 32:40-66.
39. McHorney C., Ware J., Raczek A. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993, 31:247-263.
40. McIntyre C.K., Miyoshita T., Setlow B., Marjon K.D., Steward O., Guzowski J.F., McGaugh J.L. Memory-influencing intra-basolateral amygdala drug infusions modulate expression of Arc protein in the hippocampus. Proceedings of the National Academy of Sciences 2005, 102:10718-10723.
41. Moneyham L., Sowell R., Seals B., Demi A. Depressive symptoms among African American women with HIV disease. Scholarly Inquiry for Nursing Practice 2000, 14:9-39.
42. Morgenstern J., Blanchard K.A., Morgan T.J., Labouvie E., Hayaki J. Testing the effectiveness of cognitive-behavioral treatment for substance abuse in a community setting: Within treatment and posttreatment findings. Journal of Consulting and Clinical Psychology 2001, 69:1007-1017.
43. Myers H.F., Durvasula R.S. Psychiatric disorders in African American men and women living with HIV/AIDS. Cultural Diversity and Ethnic Minority Psychology 1999, 5:249-262.
44. Olatunji B.O., Williams N.L., Sawchuk C.N., Lohr J.M. Disgust, anxiety and fainting symptoms associated with blood-injection-injury fears: A structural model. Journal of Anxiety Disorders 2006, 20:23-41.
45. Parsons J.T., Rosof E., Mustanksi B. Medication adherence mediates the relationships between adherence self-efficacy and biological assessments of HIV health among those with alcohol use disorders. AIDS and Behavior 2007, 12:95-103.
46. Remien R.H., Hirky A.E., Johnson M.O., Whittier D., Minh Le G., Weinhardt L.S. Adherence to medication treatment: A qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four U.S. cities. AIDS and Behavior 2003, 7:61-72.
47. Rounsaville B.J. Treatment of cocaine dependence and depression. Biological Psychiatry 2004, 56:803-809.
48. Safren S., Otto M., Worth J. Life-Steps: Applying cognitive behavioral therapy to HIV medication adherence. Cognitive and Behavioral Practice 1999, 6:332-341.
49. Safren S.A., Otto M.W., Worth J., Salomon E., Johnson W., Mayer K., Boswell S. Two strategies to increase adherence to HIV antiretroviral medication: Life-Steps and medication monitoring. Behavior Research Therapy 2001, 39:1151-1162.
50. Safren S.A., O'Cleirigh C., Tan J.Y., Raminani S.R., Reilly L.C., Otto M.W., Mayer K.H. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychology 2009, 28:1-10.
51. Shoptaw S., Peck J., Reback C.J., Rotheram-Fuller E. Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment. Journal of Psychoactive Drugs 2003, 35(Suppl. 1):161-168.
52. Simoni J.M., Frick P.A., Pantalone D.W., Turner B.J. Antiretroviral adherence interventions: A review of current literature and ongoing studies. Topics in HIV Medicine 2003, 11:185-198.
53. Simoni J.M., Kurth A.E., Pearson C.R., Merrill J.O., Frick P.A., Pantalone D.W. Self-Report measures of antiretroviral therapy adherence: a review with recommendations for hiv research and clinical management. AIDS and Behavior 2006, 10:227-245.
54. Simpson D.D., Joe G., Broome K.M., Hiller M., Knight K., Rowan-Szal G. Program diversity and treatment retention rates in the Drug Abuse Treatment Outcome Study (DATOS). Psychology of Addictive Behaviors 1997, 11:279-293.
55. Sobell L., Maisto S., Sobell M., Cooper A. Reliability of alcohol abusers' self-reports of drinking behavior. Behavioral Research Therapy 1979, 17:157-160.
56. Stein M.S., Miller A.H., Trestman R.L. Depression, the immune system, and health and illness. Archives of General Psychiatry 1991, 48:171-177.
57. Treisman R., Alberts A.S., Sahai E. Regulation of SRF activity by Rho family GTPases. Cold Spring Harbor Symposia on Quantitative Biology 1998, 63:643-651.
58. Ware J.E., Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. Journal of Clinical Epidemiology 1998, 51:903-912.
59. Ware J., Kosinski M., Keller S. SF-36 Physical and Mental Health Summary Scales: A user's manual. Boston: The Health Institute, New England Medical Center 1994, 8:23-28.
60. Woods W., Lindan C., Hudes E., Boscarino J., Clark W., Avins A. HIV infection and risk behaviors in two cross-sectional surveys of heterosexuals in alcoholism treatment. Journal of Studies on Alcohol 2000, 61:262-266.